These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11745224)

  • 1. Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma.
    Francini G; Petrioli R; Gonnelli S; Correale P; Pozzessere D; Marsili S; Montagnani A; Lucani B; Rossi S; Monaco R; Manganelli A; Salvestrini F; Fiaschi AI
    Cancer; 2001 Sep; 92(6):1468-74. PubMed ID: 11745224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA 15.3 with urinary calcium excretion is useful in the diagnosis and monitoring of bone metastases from breast cancer.
    Yadav GC; Rao A; Motawy MM; Safadi N; Ahmed MJ
    Int J Biol Markers; 1993; 8(4):208-14. PubMed ID: 8138660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Is skeletal alkaline phosphatase a valid staging marker in detection of osteoblastic skeletal metastases of prostate carcinoma?].
    Wirtz DC; Wolff JM; Ittel TH; Jakse G; Niethard FU
    Z Orthop Ihre Grenzgeb; 1998; 136(3):255-9. PubMed ID: 9736988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma.
    Berruti A; Tucci M; Dogliotti L; Scarpa RM; Angeli A
    Cancer; 2002 Sep; 95(5):1182-3; author reply 1183-4. PubMed ID: 12209706
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
    Unni Mooppan MM; Kim H; Wang JC; Tobin MS; Wax SH
    Prostate; 1983; 4(4):397-405. PubMed ID: 6191318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease.
    Pecherstorfer M; Zimmer-Roth I; Schilling T; Woitge HW; Schmidt H; Baumgartner G; Thiébaud D; Ludwig H; Seibel MJ
    J Clin Endocrinol Metab; 1995 Jan; 80(1):97-103. PubMed ID: 7829646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers of bone turnover in prostate cancer.
    Garnero P
    Cancer Treat Rev; 2001 Jun; 27(3):187-92; discussion 193-6. PubMed ID: 11417970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
    Body JJ; Dumon JC; Gineyts E; Delmas PD
    Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can serum prostate-specific antigen replace bone scintigraphy in the follow-up of metastatic prostatic cancer?
    Sissons GR; Clements R; Peeling WB; Penney MD
    Br J Radiol; 1992 Oct; 65(778):861-4. PubMed ID: 1384917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
    Morote J; Lorente JA; Encabo G
    Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
    Petrioli R; Rossi S; Caniggia M; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Salvestrini F; Manganelli A; Francini G
    Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy.
    Ruckle HC; Klee GG; Oesterling JE
    Mayo Clin Proc; 1994 Jan; 69(1):69-79. PubMed ID: 7505870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
    Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
    Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium excretion in metastatic prostatic carcinoma.
    Grainger R; Reda M; Fitzpatrick JM
    Br J Urol; 1984 Dec; 56(6):687-9. PubMed ID: 6534491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is bone scintigraphy necessary in initial staging of prostate cancer patients?
    Jaukovic L; Adjinovic B; Cerovic S; Joksimovic M; Soldatovic Z
    Hell J Nucl Med; 2011; 14(2):126-30. PubMed ID: 21761013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
    Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
    Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
    Smith MR; Kabbinavar F; Saad F; Hussain A; Gittelman MC; Bilhartz DL; Wynne C; Murray R; Zinner NR; Schulman C; Linnartz R; Zheng M; Goessl C; Hei YJ; Small EJ; Cook R; Higano CS
    J Clin Oncol; 2005 May; 23(13):2918-25. PubMed ID: 15860850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.